NXGL

Adam E. Drapczuk III

Known title: Chief Financial OfficerCIK: 0001867086

Adam E. Drapczuk III's purchase track record

How the stock did after each of Adam E. Drapczuk III's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.

Purchases measured
4
of 4 since May 27, 2022
Stock higher 6 months later
50%
3 months: 75%
Median 6-month return
-0.4%
3 months: +7.9%
Beat the S&P 500
50%
median -3.8% vs. index
PurchaseStockAmount3 months6 months
11/20/2024NXGL$48K+6.1%-32.7%
8/23/2024NXGL$25K+27.7%+27.7%
3/1/2024NXGL$100K-13.9%+19.7%
5/27/2022NXGL$32K+9.8%-20.5%

Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 7, 2026

NXGL Listed Among 12 Health Care Stocks Moving in Pre‑Market Session. NXGL was one of 12 health‑care stocks that moved in Wednesday’s pre‑market session. The move reflects short‑term interest in the sector. The stock is trading near its 52‑week low and has a low RSI, which may have contributed to the pre‑market activity.

this person other insiders at NXGL

Transaction History

NXGL▲ Buy$48K
NXGL▲ Buy$25K
NXGL▲ Buy$100K
NXGL▲ Buy$8K
NXGL▲ Buy$24K

We use analytics to understand how market-wall is used. No personal data is sold.